February 2026 in “Journal of Dermatology and Skin Science” This review highlights that obsessive-compulsive disorder and body-focused repetitive behaviors are increasingly encountered in dermatology, often going undetected, and emphasizes the role of dermatologists in early identification and interdisciplinary treatment to address both physical and psychological aspects for improved outcomes.
56 citations
,
July 2014 in “PLoS ONE” This study found that midazolam improved PTSD-associated behavioral deficits in rats through its action on the TSPO, CBR, and neurosteroidogenesis pathways.
24 citations
,
January 2021 in “Physiological Research” This review addresses the effects of testosterone on brain development and examines both the established sex differences in brain functions and the debate surrounding structural dimorphism in neuropsychiatric conditions.
2 citations
,
December 2019 in “Neurobiology of Stress” This review discusses the potential link between early postnatal allopregnanolone levels and vulnerability to drug abuse in adulthood, noting a need for more in-depth studies to confirm this relationship.
August 2008 in “European Neuropsychopharmacology” This study identified significant correlations between self-esteem, psychiatric symptoms, and health-related quality of life in peritoneal dialysis patients.
13 citations
,
January 2020 in “Neuroscience” This study found that finasteride impaired object recognition memory and altered hippocampal dendritic structures in male 3xTg-AD mice, suggesting potential sex differences in Alzheimer's disease pathology.
4 citations
,
June 2024 in “Journal of pharmacopuncture” This review compiles current experimental research on Alzheimer's and cognitive impairment models, highlighting the potential of *Polygonum multiflorum* for treating neurological disorders and suggesting a foundation for future clinical trials.
1 citations
,
January 2017 in “Spectrum Research Repository (Concordia University)” This study found that young women with PCOS exhibited altered white matter microstructure and reduced cognitive performance compared to matched controls.
April 2026 in “Frontiers in Pharmacology” This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.
June 2022 in “Research Square (Research Square)” In this study, higher DHA/omega-6 fatty acid ratios were linked to increased social impairment in individuals with autism, alongside lower antioxidant enzyme levels and higher markers of lipid peroxidation.
182 citations
,
June 2002 in “Journal of Neuroscience” This study suggests that apoE4 may contribute to cognitive decline by reducing androgen receptor levels in the brain, but androgen treatment improved memory deficits in female mice expressing human apoE4.
18 citations
,
September 2021 in “Journal of Neuroendocrinology” This review discusses how neurosteroids acting on GABAA receptors may influence behavior and explores the potential for developing selective modulators for treating psychiatric disorders, but reports no new clinical results.
17 citations
,
September 2013 in “The International Journal of Neuropsychopharmacology” This study found that neonatal finasteride treatment in male rats altered hippocampal GABAA receptor subunit expression and led to increased anxiety-like behavior in response to progesterone in adulthood.
13 citations
,
December 2017 in “CNS Neuroscience & Therapeutics” In this study, finasteride was found to inhibit the dopaminergic system and reduce open-field behaviors in adolescent male rats by decreasing dopamine levels and related proteins.
81 citations
,
June 2014 in “American Journal of Men's Health” This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.
77 citations
,
October 2007 in “International Journal of Andrology” This study found that testosterone replacement, with or without finasteride, did not lead to significant cognitive improvements over 36 months in healthy older men without prior cognitive impairment.
May 2026 in “Pacific Rim International Journal of Nursing Research” In this study of Thai women with ovarian cancer receiving chemotherapy, researchers found that symptom experiences such as numbness, tingling, and fatigue were frequent and significantly affected quality of life, while the effectiveness of symptom management did not significantly predict quality of life.
April 2026 in “npj Parkinson s Disease” This study found that VPS13C variants are significantly enriched in patients with idiopathic REM sleep behavior disorder (iRBD), associating these variants with more severe symptoms, autonomic dysfunction, and faster progression from iRBD to overt α-synucleinopathy in the iRBD-first disease subtype.
January 2025 in “Medical Research Archives” In this review, researchers reported that anorexia nervosa leads to widespread medical complications across all body systems, particularly at low body weights, and these complications are primarily treated through nutritional rehabilitation with a multidisciplinary team approach.
January 2024 in “Journal of Biosciences and Medicines” In this study, combining Ginkgo biloba extract dropping pills with butylphthalide capsules improved cognitive and neurological function, daily living activities, and reduced inflammatory responses in patients with cognitive dysfunction following an acute ischemic stroke, compared to butylphthalide treatment alone.
37 citations
,
September 2018 in “Psychoneuroendocrinology” This study found that finasteride treatment in male rats led to enduring effects on depressive-like behavior, hippocampal neurogenesis and neuroinflammation, and gut microbiota composition after withdrawal.
April 2019 in “SUNScholar (Stellenbosch University)” This study found that cognitive working memory training may help reduce symptoms of hair-pulling disorder and improve neurocognitive functions in affected individuals.
47 citations
,
January 2016 in “Brain Behavior and Immunity” 5α-reduced progestogens may reduce mood issues and brain damage linked to HIV-1 Tat.
July 2024 in “Behavioural Brain Research” In this study, male Wistar rats with obesity showed reduced depressive-like behaviors, brain inflammation, and oxidative stress after long-term finasteride treatment, suggesting potential benefits of finasteride in obese conditions, while lean rats experienced adverse effects including metabolic disturbances and depressive-like behaviors.
38 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This review discusses psychocutaneous syndromes, detailing their classifications and management strategies, but reports no new clinical findings; it underscores dermatologists' role in these cases.
May 2025 in “Psychopharmacology” In this study, chronic finasteride administration in male rats led to depression- and anxiety-like behaviors only in specific tests and moderately affected hippocampal synaptic plasticity, possibly due to adaptive plasma corticosterone level changes over time.
February 2023 in “Frontiers in Endocrinology” In this study, prenatal androgen exposure was linked to altered sexual behaviors in both male and female mice, with specific effects on mounting and lordosis behaviors.
186 citations
,
February 2015 in “Frontiers in Neuroscience” This review discusses the complex effects of testosterone on the brain, emphasizing sex differences, and reports no clinical results; the authors highlight the inconsistencies in current study findings.
30 citations
,
March 2001 in “Environmental Health Perspectives” This review explores the significant impacts of hormonal changes within normal physiological ranges and suggests examining low-dose effects from chemicals disrupting hormonal activity; it presents no new clinical results.
451 citations
,
March 2005 in “Endocrine Reviews” This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.